Natco pharma inks deal with Mylan

New Delhi, June 11 (UNI) Hyderabad-based Natco Pharma Ltd today said it has entered an agreement with Pittsburgh-based Mylan Inc for worldwide marketing and distribution of glatiramer acetate used for treating multiple sclerosis.

''Natco has signed a licence and supply agreement with Mylan for its glatiramer acetate pre-filled syringes, a generic version of Teva Pharmaceutical's CopaxoneR,'' the company said in a statement.

The agreement will enable Mylan exclusive distribution rights in the US and all major markets in Europe, Australia, New Zealand, Japan and Canada, and includes an option to expand into additional territories.

Natco has commercialised its glatiramer acetate product in India and the Ukraine, and the company has US Food and Drug Administration (FDA) approved manufacturing facilities both for active pharmaceutical ingredients (APIs) as well as for finished dosage pharmaceutical formulations, the statement said.

UNI AK SG BST1159